98%
921
2 minutes
20
RNase H-dependent antisense oligonucleotides (gapmer ASOs) represent a class of nucleic acid therapeutics that bind to target RNA to facilitate RNase H-mediated RNA cleavage, thereby regulating the expression of disease-associated proteins. Integrating artificial nucleic acids into gapmer ASOs enhances their therapeutic efficacy. Among these, amido-bridged nucleic acid (AmNA) stands out for its potential to confer high affinity and stability to ASOs. However, a significant challenge in the design of gapmer ASOs incorporating artificial nucleic acids, such as AmNA, is the accurate prediction of their melting temperature ( ) values. The is a critical parameter for designing effective gapmer ASOs to ensure proper functioning. However, predicting accurate values for oligonucleotides containing artificial nucleic acids remains problematic. We developed a prediction model using a library of AmNA-containing ASOs to address this issue. We measured the values of 157 oligonucleotides through differential scanning calorimetry, enabling the construction of an accurate prediction model. Additionally, molecular dynamics simulations were used to elucidate the molecular mechanisms by which AmNA modifications elevate , thereby informing the design strategies of gapmer ASOs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339022 | PMC |
http://dx.doi.org/10.1016/j.omtn.2024.102272 | DOI Listing |
Nucleic Acid Ther
August 2025
Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Intrathecally administered RNase H1-active gapmer antisense oligonucleotides (ASOs) are promising therapeutics for brain diseases where lowering the expression of one target gene is expected to be therapeutically beneficial. Such ASOs are active, to varying degrees, across most or all cell types in the cortex and cerebellum of mouse and non-human primate (NHP) brain regions with substantial drug accumulation. Intrathecally delivered ASOs, however, exhibit a gradient of exposure across the brain, with more limited drug accumulation and weaker target engagement in deep brain regions of NHP.
View Article and Find Full Text PDFBioconjug Chem
August 2025
Department of Life Science and Technology, Institute of Science Tokyo, Yokohama, Kanagawa 226-8501, Japan.
Prodrug-type antisense oligonucleotides (ASOs) offer spatiotemporal control of gene silencing via external stimuli or intracellular enzyme activation. However, a robust dual switch-off mechanism for phosphorothioate (PS)-modified gapmer ASOs, particularly involving topological constraints, has been largely unexplored. This study aimed to design and synthesize novel β-galactosidase-responsive cyclic ASOs that achieve controlled RNA cleavage through both inhibited Watson-Crick base pairing and topological constraints.
View Article and Find Full Text PDFNucleic Acid Ther
August 2025
Medical Research Council Nucleic Acid Therapy Accelerator, Research Complex at Harwell, Didcot, UK.
The efficacy of nucleic acid therapeutics (NATs) such as antisense oligonucleotides (ASOs) and small interfering RNAs relies on multiple stages of extra- and intracellular trafficking. Assessing uptake and efficacy often relies on fluorescent tagging of the NAT for imaging, although the exogenous tag undoubtedly influences the kinetics of intracellular transport and does not represent the compound used clinically. Therefore, better methods to assess the cellular and tissue distribution of NATs are needed.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
September 2025
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen 6525 GA, the Netherlands.
Myotonic dystrophy type 1 (DM1) is caused by a (CTG) expansion in the gene, leading to a multisystemic manifestation and broad disease presentation. Although the DM1 phenotype and onset correlate with expansion length, understanding DM1 etiology and developing effective therapies remains challenging. Here, we investigated the contribution of repeat length on aberrant splicing and response to antisense oligonucleotides (ASOs).
View Article and Find Full Text PDFChem Sci
July 2025
Department of Chemistry, University of Oxford Mansfield Road Oxford OX1 3TA UK
Antisense oligonucleotides (ASOs) can modulate gene expression at the mRNA level, providing the ability to tackle conventionally undruggable targets and usher in an era of personalized medicine. A key mode of action for ASOs relies upon RNase H-engagement in the nucleus, however, most mature mRNA is present in the cytoplasm. This disconnect limits the efficacy and biomedical applications of ASOs.
View Article and Find Full Text PDF